Tritonpoint Wealth LLC Purchases 1,270 Shares of Bristol-Myers Squibb (NYSE:BMY)

Tritonpoint Wealth LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 4.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,775 shares of the biopharmaceutical company’s stock after acquiring an additional 1,270 shares during the quarter. Tritonpoint Wealth LLC’s holdings in Bristol-Myers Squibb were worth $1,694,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. LaFleur & Godfrey LLC boosted its holdings in shares of Bristol-Myers Squibb by 3.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock worth $2,463,000 after purchasing an additional 1,487 shares during the period. Brighton Jones LLC increased its position in shares of Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sovran Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $274,000. Avestar Capital LLC increased its position in shares of Bristol-Myers Squibb by 31.6% during the fourth quarter. Avestar Capital LLC now owns 14,890 shares of the biopharmaceutical company’s stock valued at $842,000 after acquiring an additional 3,575 shares in the last quarter. Finally, Catalyst Financial Partners LLC grew its position in Bristol-Myers Squibb by 24.0% in the 4th quarter. Catalyst Financial Partners LLC now owns 7,709 shares of the biopharmaceutical company’s stock worth $436,000 after purchasing an additional 1,490 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $49.71 on Friday. The company has a market capitalization of $101.15 billion, a price-to-earnings ratio of -11.25, a PEG ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The firm’s 50-day moving average is $48.71 and its 200 day moving average is $54.77. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.40) EPS. Research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BMY. Jefferies Financial Group dropped their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 target price on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.